tbuckley/cabot-search huggingface dataset:
For Want of a Sail
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Calcium and phosphate requirements of preterm infants who require prolonged hyperalimentation
Authors: P. J. Knight
Journal: JAMA (1980)

Preterm infants require large amounts of calcium and phosphate to maintain skeletal mineralization during prolonged hyperalimentation. It is impossible to supply the amount of calcium and phosphate normally acquired transplacentally (150 mg/kg/day of calcium and 80 mg/kg/day of phosphate) with reasonable volumes of a single hyperalimentation solution of a physiological pH. We recently encountered calcium phosphate precipitates plugging our hyperalimentation catheters as we tried to raise the calcium concentration above 20 mEq of calcium per liter of hyperalimentation solution. Such a solution supplies 50 mg/kg/day of calcium when run at 125 mL/kg/day. In an attempt to circumvent this problem, we are currently using two hyperalimentation solutions—one high in calcium and the other high in phosphates—run alternately for 12-hour periods. This regimen supplies 80 mg/kg/day of calcium. (<i>JAMA</i>243:1244-1246, 1980)
AN INDEX OF AMERICAN MEN OF SCIENCE.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033
Authors: Johann S. de Bono
Journal: European Urology (2016)
Correction
Journal: BMJ (1947)

ANY QUESTIONS?MEICLSH MEDICAL ]O(UR?4ALIntramuscular or Subcutaneous Injections Q.-Intramuscular injections can be a nuisance to both doctor and patient.What is the objection to giving liver extract or penicillin subcutaneously ?Relative slowness of absorption would often seem to be an advantage.The same applies to oily solution of progesterone and oestradiol.One firm recomn- mends that progesterone be given intramuscularly, and oestradiol "intramuscularly or subcutaneously."It is agreed that certain drugs are best given by special routes for speed of action or other reason, but does not the matter too often depend on the whim of the manufacturer ?
Health Concepts, Issues, and Experience in the Abakaliki Area, Nigeria
Authors: Chrysanthus Chukwuma
Journal: Environmental Health Perspectives (1994)

Environmental health problems are increasingly receiving global attention. The health of entire nations may not only be affected by adverse environmental conditions, but by nutritional deficiencies that lead to morbidity and mortality. The type and extent of adverse health effects in a population depend on the potential for exposure to some environmental factors and pathogens as well as other environmental variables like industrialization, sanitation conditions, and urbanization. National and international comparisons between health status indicators can reveal the extent of any differences that exist, including dynamic changes in prevailing environmental conditions which may be helpful in characterizing the role of specific risk factors. Improvements in collection of environmental data related to health can help to identify, control, and eliminate many of the factors that are associated with environmental risk in the Abakaliki area of eastern Nigeria.
Correction
Authors: J Pitzsimons, W Blenkinsopp, P Rycroft, G Farrer-Brown, -Up Chir, M Slapak, -Up Raine, M Andrews, M Baecker, C Edward, L Kershaw, D Mcadie, B Nunn, R Olusanys, J Parker, M Glasgow, D.-G Addis, L Sheila, D Duncan, M Kyi, M Molokhia, Dorothy Younie, Austin Hill, Annis Gillie, J Smythies, D.-A Dayan, A El, Rahman Ali, M El-Mahdi Badran, S El, S El Masry, Carolyn Giles, Laila Sekla, Eliza- Beth Asheskov, A Hamilton, M Kanm, Susan Poston, A Radwan, C Schorah, Appointmtents Manchester, D Bulmer, A Pisher, J Evanson, Mr Mcneill Orr, R Stirland, D Davies, A Jones, D Walsh, C Koop, K Heaton, J Jones, D Jackson, P Shaw, J Powell, Mr Smythe Golby, B Wharton, D.-B Burns, A Cooper, J Hayes, J Thomas, M.-R Cha, M Dundee, -C Davies, I El-Sharif, S Hcaney, J Kelly, -F Audeau, A Bal, L-H Carless, P Chan, A East, M Ghaffar, K Gindi, T Haldar, S Izzat, V Jayaram, I Kakkar, R Nuseibeh, P Pinto, M Razvi, . Sharma, Hrsalth.-C Cramer, A Arys, D Crawford, D Fanning, D Haupt, C Picton-Robinson, J Ruys, D Wallace
Journal: BMJ (1968)
Selenium and Vitamin E Supplementation for Cancer Prevention
Authors: Margaret P. Rayman
Journal: JAMA (2009)

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) by Dr Lippman and 3 colleagues 1 reported that selenium or vitamin E alone or in combination did not prevent prostate 4 cancer.The negative results of this trial confirm the outcomes in the Nutritional Prevention of 5 Cancer (NPC) Trial for those participants with the highest baseline plasma selenium 6 concentration prior to supplementation with selenized yeast. 2 The conclusion from both NPC and 7 SELECT is that daily selenium supplementation will not benefit all persons.Cancer risk 8 reduction with selenium should be expected only in men with low or suboptimal levels prior to 9 supplementation.10 11
Send Us Your Chemicals
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Polyarteritis Nodosa in Infancy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New anticancer drug class
Authors: M. L. Fuerst
Journal: JAMA (1983)

Two semisynthetic derivatives of the plant genus<i>Podophyllum</i>have received high marks in clinical trials on patients with small-cell lung cancer. One of the two chemically similar compounds, etoposide (VP16), has recently been recommended for approval as an anti-cancer agent by the Food and Drug Administration's oncology advisory committee. The other, teniposide (VM26), has shown promise in limited trials. Podophyllum extracts have a long history of medical use. Hundreds of years ago, Native Americans made cathartics from aqueous extracts of the roots of one particular<i>Podophyllum</i>species, the American mayapple. American colonists subsequently used another extract, podophyllin, as an emetic, and it was included in the first<i>United States Pharmacopoeia</i>in 1820. Currently, podophyllin is used as a topical caustic agent in treating condyloma acuminatum. Over the last 10 years, VP16 and VM26 have undergone extensive clinical evaluation in the treatment of cancer patients. Three years ago, they were approved
American Medical Association concepts of nutrition and health. Council on Scientific Affairs
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Associations of Blood Pressure and Hypertension with Lead Dose Measures and Polymorphisms in the Vitamin D Receptor and d-Aminolevulinic Acid Dehydratase Genes
Authors: Byung-Kook Lee, Gap-Soo Lee, Walter F. Stewart, Kyu-Dong Ahn, David Simon, Karl T. Kelsey, Andrew C. Todd, Brian S. Schwartz
Journal: Environmental Health Perspectives (2001)

Evidence suggests that lead and selected genes known to modify the toxicokinetics of leadnamely, those for the vitamin D receptor (VDR) and δ-aminolevulinic acid dehydratase (ALAD)-may independently influence blood pressure and hypertension risk.We report the relations among ALAD and VDR genotypes, three lead dose measures, and blood pressure and hypertension status in 798 Korean lead workers and 135 controls without occupational exposure to lead.Lead dose was assessed by blood lead, tibia lead measured by X-ray fluorescence, and dimercaptosuccinic acid (DMSA)-chelatable lead.Among lead workers, 9.9% (n = 79) were heterozygous for the ALAD 2 allele, and there were no ALAD 2 homozygotes; 11.2% (n = 89) had at least one copy of the VDR B allele, and 0.5% (n = 4) had the BB genotype.In linear regression models to control for covariates, VDR genotype (BB and Bb vs. bb), blood lead, tibia lead, and DMSAchelatable lead were all positive predictors of systolic blood pressure.On average, lead workers with the VDR B allele, mainly heterozygotes, had systolic blood pressures that were 2.7-3.7 mm Hg higher than did workers with the bb genotype.VDR genotype was also associated with diastolic blood pressure; on average, lead workers with the VDR B allele had diastolic blood pressures that were 1.9-2.5 mm Hg higher than did lead workers with the VDR bb genotype (p = 0.04).VDR genotype modified the relation of age with systolic blood pressure; compared to lead workers with the VDR bb genotype, workers with the VDR B allele had larger elevations in blood pressure with increasing age.Lead workers with the VDR B allele also had a higher prevalence of hypertension compared to lead workers with the bb genotype [adjusted odds ratio (95% confidence interval) = 2.1 (1.0, 4.4), p = 0.05].None of the lead biomarkers was associated with diastolic blood pressure, and tibia lead was the only lead dose measure that was a significant predictor of hypertension status.In contrast to VDR, ALAD genotype was not associated with the blood pressure measures and did not modify associations of the lead dose measures with any of the blood pressure measures.To our knowledge, these are the first data to suggest that the common genetic polymorphism in the VDR is associated with blood pressure and hypertension risk.We speculate that the BsmI polymorphism may be in linkage disequilibrium with another functional variant at the VDR locus or with a nearby gene.
Avoiding autocannibalism.
Authors: R J Ross, J P Miell, C R Buchanan
Journal: BMJ (1991)

Trauma, sepsis, and surgery increase the catabolic rate.If: hypercatabolism is prolonged the resultant muscle wasting and impaired immune response delay recovery.'The term autocannibalism has been used to describe this self destruc- tive response to illness,2 and a malnourished state, due to increased catabolism, remains a common problem on many hospital wards.In the 1930s Cuthbertson showed that even relatively minor trauma, such as a fractured tibia, was associated with a greatly increased catabolic rate and negative nitrogen balance (indicating net muscle loss).'The breakdown of protein after trauma may have short term advantages-for example, providing amino acids for wound healing and for synthesising acute phase proteins in the liver.Critically ill patients remain in negative nitrogen balance for long periods despite enteral or parenteral nutrition.4Although parenteral nutrition supports protein synthesis, its capacity to do so falls short of the demands of catabolism.Other ways of promoting anabolism and preventing cata- bolism have been proposed.Insulin improves nitrogen bal- ance in patients with trauma, but this effect is short lived.56Growth hormone, with its promotion of lipolysis, muscle synthesis, and the retention of nitrogen, is a logical choice for improving the nutritional state of the critically ill.The recent production of recombinant human growth hormone and its associated peptide insulin-like growth factor 1 has allowed further investigation of these compounds' anabolic potential.Growth hormone has direct actions (lipolysis and insulin antagonism) and direct anabolic actions, which are mediated by insulin-like growth factor 1. Fasting normal subjects and critically ill patients become relatively insensitive to growth hormone, with increased basal concentrations of the hormone associated with low concentrations of insulin-like growth factor 1.78 These observations suggest that the metabolic actions of growth hormone undergo adaptive change during sickness and fasting.9Consequently, the indirect anabolic actions of growth hormone are reduced while the raised basal growth hormone concentrations promote increased lipolysis and insulin antagonism.Such changes might benefit fasting sick patients by providing metabolic fuels but at the cost of switching off protein synthesis.However, in the context of modern intensive care, where nutritional support is available, this could be counterproductive, with adverse effects on wound healing, muscle strength, and recovery.Recent studies with recombinant growth hormone have
Liposomes embark on rescue mission to make highly toxic drugs more useful
Authors: C. A. Raymond
Journal: JAMA (1987)

DRUGS ARE intended to "rescue" patients from disease, but liposome technology may rescue some drugs whose use now is limited by dose-related toxicity, according to investigators conducting or planning clinical trials of liposomal formulations for this purpose. While questions remain about the feasibility and efficacy of liposome-encapsulated drugs, they are further along the path to the bedside than many other targeted drug-delivery systems. (Please see accompanying article.) One recent review predicts that more than a dozen therapies based on this technique will reach market within the decade (<i>Sci Am</i>, January 1987, pp 103-111). Liposomes are based on a simple principle: oil and water don't mix. Phospholipids, the stuff of cell membranes, are amphipathic—they have a hydrophilic head and a hydrophobic tail. Adding water to phospholipids forces them to form bilayered vesicles, resulting in the formation of small lipid membranes enclosing water. During vesicle formation, lipid-soluble drug molecules can be incorporated
A dictionary of American social reform.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DOMESTIC CORRESPONDENCE.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal